Form 8-K - Current report:
SEC Accession No. 0000950170-22-015573
Filing Date
2022-08-08
Accepted
2022-08-08 16:32:09
Documents
13
Period of Report
2022-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stro-20220808.htm   iXBRL 8-K 55739
2 EX-99.1 stro-ex99_1.htm EX-99.1 264682
  Complete submission text file 0000950170-22-015573.txt   453792

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT stro-20220808.xsd EX-101.SCH 2464
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT stro-20220808_lab.xml EX-101.LAB 13466
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT stro-20220808_pre.xml EX-101.PRE 10989
7 EXTRACTED XBRL INSTANCE DOCUMENT stro-20220808_htm.xml XML 4752
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 221144874
SIC: 2836 Biological Products, (No Diagnostic Substances)